YOLT-203
Phase 1Small molecule
YOLT-203 is one of 7 small molecule programs targeting Primary Hyperoxaluria. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Primary Hyperoxaluria
#DrugCompanyPhaseTrials
1Givlaari
Alnylam PharmaceuticalsApproved
Cystadane
RRECORDATI GROUP
Phase 2
Diacomit
BBiocodex
Phase 2
Oxalobacter Formigenes
OOxThera
Phase 2
ALLN-177
AAllena Pharmaceuticals
Phase 2
DCR-PHXC
DDicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 1
YOLT-203
RRenJi Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Primary Hyperoxaluria2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YOLT-203. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- RRenJi Hospital